aTyr Pharma Inc - Company Profile
Powered by 
All the sales intelligence you need on aTyr Pharma Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how aTyr Pharma Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with aTyr Pharma Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
ATyr Pharma Inc (ATyr Pharma) is a clinical-stage biotechnology company to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. The company's pipeline products include Efzofitimod which treats pulmonary sarcoidosis, scleroderma-associated interstitial lung disease, chronic hypersensitivity pneumonitis and connective tissue disease-related interstitial lung disease; ATYR0101 for fibrosis; and ATYR0750 targets liver disorders. It utilizes tRNA synthetase biology platform, a novel set of potential physiological modulators to identify new tRNA synthetase based drug candidates for product development. The company operates in the Hong Kong and the US. ATyr Pharma is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
Suite 300, 10240 Sorrento Valley Road, San Diego, California, 92121
Website
www.atyrpharma.com
Telephone
1 302 6587581
No of Employees
56
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ATYR (NASD)
Revenue (2024)
$190,000
-19.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-15.8%
(2024 vs 2023)
Market Cap*
$64.1M
Net Profit Margin (2024)
XYZ
-43.2%
(2024 vs 2023)
* As of and is in US$
aTyr Pharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Efzofitimod: |
| Pulmonary Sarcoidosis |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | aTyr Pharma Inc | Merck & Co Inc | GSK plc | Boehringer Ingelheim International GmbH | Xencor Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Germany | United States of America |
| City | San Diego | Rahway | London | Ingelheim am Rhein | Pasadena |
| State/Province | California | New Jersey | England | Rheinland-Pfalz | California |
| No. of Employees | 56 | 75,000 | 66,841 | 54,300 | 260 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Timothy P. Coughlin | Chairman | Executive Board | 2024 | 58 |
| Sanjay S. Shukla, M.D. | Chief Executive Officer; Director; President | Executive Board | 2017 | 53 |
| Jill M. Broadfoot | Chief Financial Officer | Senior Management | 2018 | 63 |
| Nancy E. Denyes | General Counsel; Secretary | Senior Management | 2019 | 57 |
| Peter Villiger | Vice President - Corporate Development | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer